Relationship between circulating BAFF serum levels with proliferating markers in patients with multiple myeloma

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Alexandrakis, Michael G ^a   Roussou, Parascevi ^b   Pappa, Constantina A ^a   Messaritakis, Ippokratis ^a   Xekalou, Athina ^a   Goulidaki, Nektaria ^a   Boula, Anna ^c   Tsirakis, George ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b SOTIRIA GENERAL HOSPITAL   (Greece)

^c Hematology Department   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; BETA 2 MICROGLOBULIN; BORTEZOMIB; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 6; KI 67 ANTIGEN; MELPHALAN; PREDNISONE; THALIDOMIDE; CYTOKINE; TNFSF13B PROTEIN, HUMAN;

ADULT; ARTICLE; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CELL INFILTRATION; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PLASMA CELL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; THERAPY EFFECT; AGED; BLOOD; CELL PROLIFERATION; GENE EXPRESSION REGULATION; MIDDLE AGED; PATHOLOGY;

AGED; B-CELL ACTIVATING FACTOR; CELL PROLIFERATION; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA;

EID: 84881504556     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/389579     Document Type: Article

References (35)

1. Caers J., Van Valckenborgh E., Menu E., Van Camp B., Vanderkerken K., Unraveling the biology of multiple myeloma disease: cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment. Bulletin du Cancer 2008 95 3 301 313 2-s2.0-42149142956 10.1684/bdc.2008.0600 (Pubitemid 351528767)
2. Demchenko Y. N., Kuehl W. M., A critical role for the NFkB pathway in multiple myeloma. Oncotarget 2010 1 1 59 68 2-s2.0-80052887167
3. Hanamura I., Stewart J. P., Huang Y., Zhan F., Santra M., Sawyer J. R., Hollmig K., Zangarri M., Pineda-Roman M., Van Rhee F., Cavallo F., Burington B., Crowley J., Tricot G., Barlogie B., Shaughnessy J. D. Jr., Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 2006 108 5 1724 1732 2-s2.0-33748196399 10.1182/blood-2006-03-009910 (Pubitemid 44316143)
4. DuVillard L., Guiguet M., Casasnovas R.-O., Caillot D., Monnier-Zeller V., Bernard A., Guy H., Solary E., Diagnostic value of serum IL-6 level in monoclonal gammopathies. British Journal of Haematology 1995 89 2 243 249 2-s2.0-0028955069
5. Tinhofer I., Marschitz I., Henn T., Egle A., Greil R., Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. Blood 2000 95 2 610 618 2-s2.0-0034651023 (Pubitemid 30041677)
6. Howard M., O'Garra A., Ishida H., de Waal Malefyt R., De Vries J., Biological properties of interleukin 10. Journal of Clinical Immunology 1992 12 4 239 247 2-s2.0-0026717311 10.1007/BF00918147
7. Lauta V. M., A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer 2003 97 10 2440 2452 2-s2.0-0038370952 10.1002/cncr.11072 (Pubitemid 36542483)
8. Pappa C., Miyakis S., Tsirakis G., Sfiridaki A., Alegakis A., Kafousi M., Stathopoulos E. N., Alexandrakis M. G., Serum levels of Interleukin-15 and Interleukin-10 and their correlation with proliferating cell nuclear antigen in multiple myeloma. Cytokine 2007 37 2 171 175 2-s2.0-34247869006 10.1016/j.cyto.2007.02.022 (Pubitemid 46694336)
9. Thaler J., Fechner F., Herold M., Huber H., Interleukin-6 in multiple myeloma: correlation with disease activity and Ki-67 proliferation index. Leukemia and Lymphoma 1994 12 3-4 265 271 2-s2.0-0028269888 (Pubitemid 24077176)
10. Kanavaros P., Stefanaki K., Vlachonikolis J., Papalazarou D., Rontogianni D., Arvanitis D., Antonakopoulos G., Gorgoulis V., Bai M., Agnantis N. J., Immunohistochemicall expression of the p53, p21/Waf-1, Rb, p16 and Ki67 proteins in multiple myeloma. Anticancer Research 2000 20 6 B 4619 4625 2-s2.0-0034351760 (Pubitemid 32141827)
11. Ingold K., Zumsteg A., Tardivel A., Huard B., Steiner Q.-G., Cachero T. G., Qiang F., Gorelik L., Kalled S. L., Acha-Orbea H., Rennert P. D., Tschopp J., Schneider P., Identification of proteoglycans as the APRIL-specific binding partners. Journal of Experimental Medicine 2005 201 9 1375 1383 2-s2.0-20844432040 10.1084/jem.20042309 (Pubitemid 40664082)
12. Moreaux J., Sprynski A.-C., Dillon S. R., Mahtouk K., Jourdan M., Ythier A., Moine P., Robert N., Jourdan E., Rossi J. F., Klein B., APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop. European Journal of Haematology 2009 83 2 119 129 2-s2.0-67650721105 10.1111/j.1600-0609.2009.01262.x
13. Novak A. J., Bram R. J., Kay N. E., Jelinek D. F., Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood 2002 100 8 2973 2979 2-s2.0-0037108558 10.1182/blood-2002- 02-0558
14. Briones J., Timmerman J. M., Hilbert D. M., Levy R., BLyS and BLyS receptor expression in non-Hodgkin's lymphoma. Experimental Hematology 2002 30 2 135 141 2-s2.0-0036141462 10.1016/S0301-472X(01)00774-3 (Pubitemid 34081224)
15. Novak A. J., Darce J. R., Arendt B. K., Harder B., Henderson K., Kindsvogel W., Gross J. A., Greipp P. R., Jelinek D. F., Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 2004 103 2 689 694 2-s2.0-0942298590 10.1182/blood-2003-06-2043 (Pubitemid 38140105)
16. Moreaux J., Legouffe E., Jourdan E., Quittet P., Rème T., Lugagne C., Moine P., Rossi J.-F., Klein B., Tarte K., BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004 103 8 3148 3157 2-s2.0-11144355586 10.1182/blood-2003-06-1984 (Pubitemid 38451693)
17. Fragioudaki M., Boula A., Tsirakis G., Psarakis F., Spanoudakis M., Papadakis I. S., Pappa C. A., Alexandrakis M. G., B cell-activating factor: its clinical significance in multiple myeloma patients. Annals of Hematology 2012 91 9 1413 1418 2-s2.0-84859918853
18. Jelinek D. F., Darce J. R., Human B lymphocyte malignancies: exploitation of BLyS and APRIL and their receptors. Current Directions in Autoimmunity 2005 8 266 288 2-s2.0-16544363235
19. Moreaux J., Cremer F. W., Reme T., Raab M., Mahtouk K., Kaukel P., Pantesco V., De Vos J., Jourdan E., Jauch A., Legouffe E., Moos M., Fiol G., Goldschmidt H., Rossi J. F., Hose D., Klein B., The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 2005 106 3 1021 1030 2-s2.0-23044512143 10.1182/blood-2004-11-4512 (Pubitemid 41076449)
20. Abe M., Kido S., Hiasa M., Nakano A., Oda A., Amou H., Matsumoto T., BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma. Leukemia 2006 20 7 1313 1315 2-s2.0-33745193755 10.1038/sj.leu.2404228 (Pubitemid 43905843)
21. Moreaux J., Hose D., Kassambara A., Reme T., Moine P., Requirand G., Goldschmidt H., Klein B., Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration. Blood 2011 117 4 1280 1290 2-s2.0-79251554364 10.1182/blood-2010-04-279760
22. Xu G., Shen X. J., Pu J., BLyS expression and JNK activation may form a feedback loop to promote survival and proliferation of multiple myeloma cells. Cytokine 2012 60 2 505 513
23. Moreaux J., Hose D., Jourdan M., Reme T., Hundemer M., Moos M., Robert N., Moine P., De Vos J., Goldschmidt H., Klein B., TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines. Haematologica 2007 92 6 803 811 2-s2.0-34347216736 10.3324/haematol.10574 (Pubitemid 350155306)
24. Rossi J.-F., Moreaux J., Hose D., Requirand G., Rose M., Rouillé V., Nestorov I., Mordenti G., Goldschmidt H., Ythier A., Klein B., Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study. British Journal of Cancer 2009 101 7 1051 1058 2-s2.0-70349675652 10.1038/sj.bjc.6605241
25. Pestka S., Krause C. D., Sarkar D., Walter M. R., Shi Y., Fisher P. B., Interleukin-10 and related cytokines and receptors. Annual Review of Immunology 2004 22 929 979 2-s2.0-2342659126 10.1146/annurev.immunol.22.012703.104622 (Pubitemid 38680445)
26. Yang M., Sun L., Wang S., Ko K.-H., Xu H., Zheng B.-J., Cao X., Lu L., Novel function of B cell-activating factor in the induction of IL-10-producing regulatory B cells. Journal of Immunology 2010 184 7 3321 3325 2-s2.0-77951640991 10.4049/jimmunol.0902551
27. Zhao Yang Lu Z. Y. L., Xue Guang Zhang X. G. Z., Rodriguez C., Wijdenes J., Gu Z.-J., Morel- Fournier B., Harousseau J. L., Bataille R., Rossi J.-F., Klein B., Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells. Blood 1995 85 9 2521 2527 2-s2.0-0028938265
28. Urbanśka-Ryś H., Wierzbowska A., Stpień H., Robak T., Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 receptor (sIL-6R) in patients with multiple myeloma. European Cytokine Network 2000 11 3 443 451 2-s2.0-0034456695 (Pubitemid 32268904)
29. Grabstein K. H., Eisenman J., Shanebeck K., Rauch C., Srinivasan S., Fung V., Beers C., Richardson J., Schoenborn M. A., Ahdieh M., Johnson L., Alderson M. R., Watson J. D., Anderson D. M., Giri J. G., Cloning of a T cell growth factor that interacts with the β chain of the interleukin-2 receptor. Science 1994 264 5161 965 968 2-s2.0-0028179054 (Pubitemid 24196167)
30. Armitage R. J., Macduff B. M., Eisenman J., Paxton R., Grabstein K. H., IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation. Journal of Immunology 1995 154 2 483 490 2-s2.0-0028798403
31. Fehniger T. A., Caligiuri M. A., Interleukin 15: biology and relevance to human disease. Blood 2001 97 1 14 32 2-s2.0-0035169507 10.1182/blood.V97.1.14 (Pubitemid 32061238)
32. Carrasco Y. R., Batista F. D., B-cell activation by membrane-bound antigens is facilitated by the interaction of VLA-4 with VCAM-1. EMBO Journal 2006 25 4 889 899 2-s2.0-33644542737 10.1038/sj.emboj.7600944 (Pubitemid 43292449)
33. Hase H., Kanno Y., Kojima M., Hasegawa K., Sakurai D., Kojima H., Tsuchiya N., Tokunaga K., Masawa N., Azuma M., Okumura K., Kobata T., BAFF/BLyS can potentiate B-cell selection with the B-cell coreceptor complex. Blood 2004 103 6 2257 2265 2-s2.0-12144286821 10.1182/blood-2003-08-2694 (Pubitemid 38326245)
34. Alexandrakis M. G., Passam F. H., Kyriakou D. S., Dambaki K., Niniraki M., Stathopoulos E., Ki-67 proliferation index: correlation with prognostic parameters and outcome in multiple myeloma. The American Journal of Clinical Oncology 2004 27 1 8 13 2-s2.0-0842327296 10.1097/01.coc.0000045810.91816.41 (Pubitemid 38176284)
35. Thomas G., Xavier L., Alain D., Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I. European Journal of Haematology 2010 10.1111/j.1600-0609.2007.0915.x